The EU Commission’s pharmaceuticals sector inquiry report signals future antitrust actions

The pharmaceuticals sector in the European Union will remain under close antitrust scrutiny in the coming years. This is confirmed by the Communication the European Commission released yesterday in which it summarizes the main conclusions from its sector inquiry that started in January 2008. Whilst the Commission identifies specific practices which it says have caused market distortions, and which are therefore likely to attract attention of antitrust enforcers, the Commission does not give further legal guidance on the application of competition law principles in this field. The most significant legal changes are rather related to the (national) regulatory environment which already has proven to be deficient and where reforms at EU level are in the making. A sector inquiry is a

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Sébastien J. Evrard, Yvan N. Desmedt, Carsten Gromotke, The EU Commission’s pharmaceuticals sector inquiry report signals future antitrust actions, 8 juillet 2009, e-Competitions July 2009, Art. N° 33770

Visites 987

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues